Real-world outcomes of asciminib versus first- and second-generation tyrosine kinase inhibitors as second-line treatment for chronic-phase chronic myeloid leukemia

Atallah EL et al. Leuk Res, October 2026 (epub ahead of print)

• Share
• Tweet
• Share
• Share